Blood thinner drugs vs aspirin to prevent clot problems
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation clinical trials.
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have PV, ET, or pre-PMF based on standard diagnosis rules
- Your test shows the JAK2 V617F mutation (with mutation level above 1%)
- You are considered “high risk” because you are over 60, or you have a prior clot history (and you’re at least 18)
- You were diagnosed with the bone marrow condition within the past 12 months
- You can take part in the study safely: no aspirin or DOAC allergy, and no major bleeding recently
- Your kidneys and liver are healthy enough for study drugs, and you can give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This study looks at certain markers in the blood to see if they can predict blood clots in people with myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. It is only for people who have a specific JAK2 mutation and are at high risk for clots, and who are already enrolled in another trial and a biobank.
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
This study compares two daily pills, aspirin and rivaroxaban, to find which is better at preventing dangerous blood clots in people newly diagnosed with multiple myeloma who are at high risk. Participants will be randomly assigned to one of the two treatments.
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
This study compares two strategies for managing atrial fibrillation (irregular heartbeat) in people on dialysis: one uses a blood thinner called apixaban to prevent strokes, and the other does not. The goal is to find out which approach is safer and more effective for this specific group.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.